Mexiletine (NaMuscla) for the treatment of myotonia in non-dystrophic myotonic disorders

References

• Koch M, Steinmeyer K, Lorenz C, et al. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science. 1992;257(5071):797–800.
   PubMed Web of Science ®Google Scholar
• Ptacek LJ, Tawil R, Griggs RC, et al. Linkage of atypical myotonia congenita to a sodium channel locus. Neurology. 1992;42(2):431–433.
   PubMed Web of Science ®Google Scholar
• Ptacek LJ, Trimmer JS, Agnew WS, et al. Paramyotonia congenita and hyperkalemic periodic paralysis map to the same sodium-channel gene locus. Am J Hum Genet. 1991;49(4):851–854.
   PubMed Web of Science ®Google Scholar
• Suetterlin K, Männikkö R, Hanna MG. Muscle channelopathies: recent advances in genetics, pathophysiology and therapy. Curr Opin Neurol. 2014;27(5):583–590.
   PubMed Web of Science ®Google Scholar
• Nagamitsu S, Matsuura T, Khajavi M, et al. A “dystrophic” variant of autosomal recessive myotonia congenita caused by novel mutations in the CLCN1 gene. Neurology. 2000;55(11):1697–1703.
   PubMed Web of Science ®Google Scholar
• Miller TM, Da Silva MD, Miller HA, et al. Correlating phenotype and genotype in the periodic paralyses. Neurology. 2004;63(9):1647–1655.
   PubMed Web of Science ®Google Scholar
• Horga A, Raja Rayan DL, Matthews E, et al. Prevalence study of genetically defined skeletal muscle channelopathies in England. Neurology. 2013;80(16):1472–1475.
   PubMed Web of Science ®Google Scholar
• Statland JM, Wang Y, Richesson R, et al. An interactive voice response diary for patients with non-dystrophic myotonia. Muscle Nerve. 2011;44(1):30–35.
   PubMed Web of Science ®Google Scholar
• Trip J, Drost G, Ginjaar HB, et al. Redefining the clinical phenotypes of non-dystrophic myotonic syndromes. J Neurol Neurosurg Psychiatry. 2009;80(6):647–652.
   PubMed Web of Science ®Google Scholar
• Trip J, de Vries J, Drost G, et al. Health status in non-dystrophic myotonias: close relation with pain and fatigue. J Neurol. 2009;256(6):939–947.
   PubMed Web of Science ®Google Scholar
• Matthews E, Fialho D, Tan SV, et al. The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain. 2010;133(1):9–22.
   PubMedGoogle Scholar
• Rosenfeld J, Sloan-Brown K, George AL. A novel muscle sodium channel mutation causes painful congenital myotonia. Ann Neurol. 1997;42(5):811–814.
   PubMed Web of Science ®Google Scholar
• Nam T-S, Choi S-Y, Park D-J, et al. The overlap between fibromyalgia syndrome and myotonia congenita. J Clin Neurol. 2015;11(2):188.
   PubMed Web of Science ®Google Scholar
• Fialho D, Schorge S, Pucovska U, et al. Chloride channel myotonia: exon 8 hot-spot for dominant-negative interactions. Brain. 2007;130(12):3265–3274.
   PubMedGoogle Scholar
• Sansone VA, Ricci C, Montanari M, et al. Measuring quality of life impairment in skeletal muscle channelopathies. Eur J Neurol. 2012;19(11):1470–1476. .
   PubMed Web of Science ®Google Scholar
• Suetterlin KJ, Bugiardini E, Kaski JP, et al. Long-term safety and efficacy of mexiletine for patients with skeletal muscle channelopathies. JAMA Neurol. 2015;72(12):1531.
   PubMed Web of Science ®Google Scholar
• Andersen G, Hedermann G, Witting N, et al. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. Brain. 2017;140(9):2295–2305.
   PubMedGoogle Scholar
• Kwieciński H, Ryniewicz B, Ostrzycki A. Treatment of myotonia with antiarrhythmic drugs. Acta Neurol Scand. 1992;86(4):371–375.
   PubMed Web of Science ®Google Scholar
• De Bellis M, Camerino DC, Desaphy J-F. Toward precision medicine in myotonic syndromes. Oncotarget. 2017;8:14279–14280.
   PubMedGoogle Scholar
• Statland JM. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA. 2012;308(13):1357.
   PubMed Web of Science ®Google Scholar
• Stunnenberg BC, Raaphorst J, Groenewoud HM, et al. Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials. JAMA. 2018;320(22):2344–2353.
   PubMed Web of Science ®Google Scholar
• Stunnenberg BC, Woertman W, Raaphorst J, et al. Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol. BMC Neurol. 2015;15(1):43.
   PubMedGoogle Scholar
• Betchel NT, Lamotrigine SA. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 [cited 2020 Feb 21]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK470442/
   Google Scholar
• Arnold WD, Kline D, Sanderson A, et al. Open-label trial of ranolazine for the treatment of myotonia congenita. Neurology. 2017;89(7):710–713.
   PubMed Web of Science ®Google Scholar
• Lorusso S, Kline D, Bartlett A, et al. Open-label trial of ranolazine for the treatment of paramyotonia congenita: ranolazine for paramyotonia. Muscle Nerve. 2019;59(2):240–243.
   PubMed Web of Science ®Google Scholar
• Volosin K, Greenberg RM, Greenspon AJ. Tocainide associated agranulocytosis. Am Heart J. 1985;109(6):1392–1393.
   PubMed Web of Science ®Google Scholar
• De Bellis M, Carbonara R, Roussel J, et al. Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity. Neuropharmacology. 2017;113:206–216.
   PubMed Web of Science ®Google Scholar
• Desaphy J-F, Modoni A, LoMonaco M, et al. Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy. Eur J Clin Pharmacol. 2013;69(4):1037–1039. .
   PubMed Web of Science ®Google Scholar
• Farinato A, Altamura C, Imbrici P, et al. Pharmacogenetics of myotonic hNav1.4 sodium channel variants situated near the fast inactivation gate. Pharmacol Res. 2019;141:224–235.
   PubMed Web of Science ®Google Scholar
• Sun C, Tranebjaerg L, Torbergsen T, et al. Spectrum of CLCN1 mutations in patients with myotonia congenita in Northern Scandinavia. Eur J Hum Genet EJHG . 2001;9(12):903–909.
   PubMed Web of Science ®Google Scholar
• Baumann P, Myllylä VV, Leisti J. Myotonia congenita in northern Finland: an epidemiological and genetic study. J Med Genet. 1998;35(4):293–296.
   PubMed Web of Science ®Google Scholar
• Jackson CE, Barohn RJ, Ptacek LJ. Paramyotonia congenita: abnormal short exercise test, and improvement after mexiletine therapy. Muscle Nerve. 1994;17(7):763–768.
   PubMed Web of Science ®Google Scholar
• Namuscla 167 mg hard capsules - summary of product characteristics (SmPC) - (emc) [Internet]. [cited 2019 Dec 19]. Available from: https://www.medicines.org.uk/emc/product/9838/smpc
   Google Scholar
• Bryant SH, Morales-Aguilera A. Chloride conductance in normal and myotonic muscle fibres and the action of monocarboxylic aromatic acids. J Physiol. 1971;219(2):367–383.
   PubMed Web of Science ®Google Scholar
• Wang GK, Russell C, Wang S-Y. Mexiletine block of wild-type and inactivation-deficient human skeletal muscle hNav1.4 Na + channels: mexiletine block of persistent late Na + currents. J Physiol. 2004;554:621–633.
   PubMed Web of Science ®Google Scholar
• Weckbecker K, Würz A, Mohammadi B, et al. Different effects of mexiletine on two mutant sodium channels causing paramyotonia congenita and hyperkalemic periodic paralysis. Neuromuscul Disord NMD. 2000;10(1):31–39.
   PubMed Web of Science ®Google Scholar
• Takahashi MP, Cannon SC. Mexiletine block of disease-associated mutations in S6 segments of the human skeletal muscle Na+ channel. J Physiol. 2001;537(3):701–714.
   PubMed Web of Science ®Google Scholar
• Desaphy JF, De Luca A, Tortorella P, et al. Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative. Neurology. 2001;57(10):1849–1857.
   PubMed Web of Science ®Google Scholar
• Desaphy J-F, Carbonara R, D’Amico A, et al. Translational approach to address therapy in myotonia permanens due to a new SCN4A mutation. Neurology. 2016;86(22):2100–2108.
   PubMed Web of Science ®Google Scholar
• Lo MM, D’Amico A, Luigetti M, et al. Effect of mexiletine on transitory depression of compound motor action potential in recessive myotonia congenita. Clin Neurophysiol. 2015;126(2):399–403.
   PubMed Web of Science ®Google Scholar
• Logigian EL, Martens WB, Moxley RT, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1(LOE Classification). Neurology. 2010;74(18):1441–1448.
   PubMed Web of Science ®Google Scholar